S&P 500   4,574.79 (+0.18%)
DOW   35,756.88 (+0.04%)
QQQ   379.12 (+0.31%)
AAPL   149.32 (+0.46%)
MSFT   310.11 (+0.64%)
FB   315.81 (-3.92%)
GOOGL   2,786.17 (+1.35%)
TSLA   1,018.43 (-0.63%)
AMZN   3,376.07 (+1.68%)
NVDA   247.17 (+6.70%)
BABA   169.99 (-3.51%)
NIO   40.47 (-1.94%)
CGC   13.17 (-2.95%)
GE   107.44 (+2.03%)
AMD   122.93 (+0.47%)
MU   68.94 (+0.26%)
T   25.37 (-1.05%)
F   15.94 (-0.38%)
ACB   7.03 (-2.09%)
DIS   172.04 (+0.02%)
PFE   43.56 (+0.95%)
BA   209.81 (-1.44%)
AMC   36.05 (-2.12%)
S&P 500   4,574.79 (+0.18%)
DOW   35,756.88 (+0.04%)
QQQ   379.12 (+0.31%)
AAPL   149.32 (+0.46%)
MSFT   310.11 (+0.64%)
FB   315.81 (-3.92%)
GOOGL   2,786.17 (+1.35%)
TSLA   1,018.43 (-0.63%)
AMZN   3,376.07 (+1.68%)
NVDA   247.17 (+6.70%)
BABA   169.99 (-3.51%)
NIO   40.47 (-1.94%)
CGC   13.17 (-2.95%)
GE   107.44 (+2.03%)
AMD   122.93 (+0.47%)
MU   68.94 (+0.26%)
T   25.37 (-1.05%)
F   15.94 (-0.38%)
ACB   7.03 (-2.09%)
DIS   172.04 (+0.02%)
PFE   43.56 (+0.95%)
BA   209.81 (-1.44%)
AMC   36.05 (-2.12%)
S&P 500   4,574.79 (+0.18%)
DOW   35,756.88 (+0.04%)
QQQ   379.12 (+0.31%)
AAPL   149.32 (+0.46%)
MSFT   310.11 (+0.64%)
FB   315.81 (-3.92%)
GOOGL   2,786.17 (+1.35%)
TSLA   1,018.43 (-0.63%)
AMZN   3,376.07 (+1.68%)
NVDA   247.17 (+6.70%)
BABA   169.99 (-3.51%)
NIO   40.47 (-1.94%)
CGC   13.17 (-2.95%)
GE   107.44 (+2.03%)
AMD   122.93 (+0.47%)
MU   68.94 (+0.26%)
T   25.37 (-1.05%)
F   15.94 (-0.38%)
ACB   7.03 (-2.09%)
DIS   172.04 (+0.02%)
PFE   43.56 (+0.95%)
BA   209.81 (-1.44%)
AMC   36.05 (-2.12%)
S&P 500   4,574.79 (+0.18%)
DOW   35,756.88 (+0.04%)
QQQ   379.12 (+0.31%)
AAPL   149.32 (+0.46%)
MSFT   310.11 (+0.64%)
FB   315.81 (-3.92%)
GOOGL   2,786.17 (+1.35%)
TSLA   1,018.43 (-0.63%)
AMZN   3,376.07 (+1.68%)
NVDA   247.17 (+6.70%)
BABA   169.99 (-3.51%)
NIO   40.47 (-1.94%)
CGC   13.17 (-2.95%)
GE   107.44 (+2.03%)
AMD   122.93 (+0.47%)
MU   68.94 (+0.26%)
T   25.37 (-1.05%)
F   15.94 (-0.38%)
ACB   7.03 (-2.09%)
DIS   172.04 (+0.02%)
PFE   43.56 (+0.95%)
BA   209.81 (-1.44%)
AMC   36.05 (-2.12%)
NASDAQ:BTAI

BioXcel Therapeutics Stock Forecast, Price & News

$30.81
+0.92 (+3.08 %)
(As of 10/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$29.94
$31.16
50-Day Range
$23.84
$32.28
52-Week Range
$23.07
$67.74
Volume225,938 shs
Average Volume411,825 shs
Market Capitalization$861.72 million
P/E RatioN/A
Dividend YieldN/A
Beta1.06
30 days | 90 days | 365 days | Advanced Chart
Receive BTAI News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


BioXcel Therapeutics logo

About BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BTAI
Employees
50
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$8.48 per share

Profitability

Net Income
$-82.17 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$861.72 million
Next Earnings Date
11/11/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.28 out of 5 stars

Medical Sector

279th out of 1,363 stocks

Pharmaceutical Preparations Industry

129th out of 667 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions

Is BioXcel Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioXcel Therapeutics stock.
View analyst ratings for BioXcel Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than BioXcel Therapeutics?

Wall Street analysts have given BioXcel Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioXcel Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BioXcel Therapeutics' next earnings date?

BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for BioXcel Therapeutics
.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) posted its earnings results on Monday, August, 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.03) by $0.08.
View BioXcel Therapeutics' earnings history
.

How has BioXcel Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

BioXcel Therapeutics' stock was trading at $29.48 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BTAI stock has increased by 4.6% and is now trading at $30.85.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BTAI?

7 analysts have issued 1-year price objectives for BioXcel Therapeutics' stock. Their forecasts range from $60.00 to $141.00. On average, they expect BioXcel Therapeutics' stock price to reach $102.43 in the next twelve months. This suggests a possible upside of 232.0% from the stock's current price.
View analysts' price targets for BioXcel Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are BioXcel Therapeutics' key executives?

BioXcel Therapeutics' management team includes the following people:
  • Vimal D. Mehta, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Richard I. Steinhart, Chief Financial Officer & Vice President
  • Frank D. Yocca, Chief Scientific Officer & Senior Vice President
  • Vincent J. O'Neill, Chief Medical Officer & Senior Vice President
  • William P. Kane, Chief Commercial Officer & Executive VP

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $30.85.

How much money does BioXcel Therapeutics make?

BioXcel Therapeutics has a market capitalization of $862.87 million. The company earns $-82.17 million in net income (profit) each year or ($3.79) on an earnings per share basis.

How many employees does BioXcel Therapeutics have?

BioXcel Therapeutics employs 50 workers across the globe.

What is BioXcel Therapeutics' official website?

The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com.

Where are BioXcel Therapeutics' headquarters?

BioXcel Therapeutics is headquartered at 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at (475) 238-6837 or via email at [email protected].


This page was last updated on 10/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.